U.S. FDA panel recommends approval of J&J's depression drug
Reuters India -

An advisory panel to the U.S. Food and Drug Administration on Tuesday recommended Johnson & Johnson's experimental nasal spray, which has a compound similar to often-abused ketamine, for patients suffering from depression.

Read this story at

Loading...

Related Articles